Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Diagnosis and Treatment of Venous Thrombosis: Current Status and Future...
share announcement

Diagnosis and Treatment of Venous Thrombosis: Current Status and Future Directions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 874

Special Issue Editor

Dr. Luis Jara-Palomares

E-Mail Website
Guest Editor
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
Interests: venous tromboembolism; cancer-associated thrombosis; deep-vein thrombosis

Special Issue Information

Dear Colleagues,

Venous thromboembolism (VTE) is a common and potentially life-threatening condition that includes deep-vein thrombosis (DVT) and pulmonary embolism (PE). The diagnosis and treatment of VTE are constantly evolving, and there are several research hot topics in this field. Some of the key points are as follows:

  • Biomarkers and novel strategies for the diagnosis or validation of previous methodologies.
  • Duration of anticoagulation: the optimal duration of anticoagulation therapy for VTE is a topic of ongoing debate.
  • Role of thrombolysis: thrombolysis is a treatment option for patients with extensive PE and is suggested for use in iliofemoral DVT, but it is associated with a higher risk of bleeding.
  • Use of compression stockings: compression stockings are often recommended to prevent post-thrombotic syndrome after a VTE, but their effectiveness is still unclear.

Overall, advances in biomarkers, anticoagulants, and the duration of therapy are improving the diagnosis and treatment of VTE, but there is still much to learn about this complex condition.

As an expert in the field, it is a great pleasure to invite you to participate in this Special Issue, entitled “Diagnosis and Treatment of Venous Thrombosis: Current Status and Future Directions”. As I am assured that you are involved in several areas in the field of VTE, we believe that you could make a brilliant contribution to this collection.

Dr. Luis Jara-Palomares
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • venous tromboembolism
  • cancer associated thrombosis
  • deep vein thrombosis
  • thrombosis
  • thrombolysis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1871 KiB  
Article
Primary Care Clinicians’ Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment
by Danielle Groat, Karlyn A. Martin, Rachel P. Rosovsky, Kristen M. Sanfilippo, Manila Gaddh, Lisa Baumann Kreuziger, Elizabeth Federici and Scott C. Woller
J. Clin. Med. 2024, 13(1), 96; https://doi.org/10.3390/jcm13010096 - 23 Dec 2023
Viewed by 712
Abstract
The direct anticoagulants (DOACs), apixaban and rivaroxaban, are used for extended-phase treatment of venous thromboembolism (VTE) and have labeling for dose reduction for this indication. The objective of this study was to better understand primary care clinician prescribing patterns of apixaban and rivaroxaban [...] Read more.
The direct anticoagulants (DOACs), apixaban and rivaroxaban, are used for extended-phase treatment of venous thromboembolism (VTE) and have labeling for dose reduction for this indication. The objective of this study was to better understand primary care clinician prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulation. We conducted a 21-question survey targeting members of the American College of Physicians and United States Veterans Administration anticoagulation management services. Survey questions covered prescribing behaviors for dose reduction of apixaban and rivaroxaban for extended VTE treatment, as well as questions related to the respondent’s practice setting. We used logistic regression to assess associations between demographics and prescribing behaviors. We used k-means clustering to identify distinct groups of prescribing patterns. Among 227 respondents, most were attending physicians (60%) and one-third (34%) practiced in internal medicine or primary care. Most (59%) indicated they dose-reduced DOACs. Hospitalists (no outpatient care) were least likely to dose-reduce (OR 0.09 [95% CI 0.03–0.22]), as well as early-career clinicians (0.53 [0.30–0.91]). Pharmacists and clinicians who treat over 500 VTE patients annually were most likely to dose reduce (6.4 [2.9–16.3]), (2.9 [1.5–6.0]), respectively. We identified five clusters of dosing behaviors and characterized clinician makeup. Clusters were primarily differentiated by frequency of dose reduction, DOAC preference, and temporary re-escalation of doses. We identified clinician characteristics that are associated with dose-reduction prescribing behaviors; these analyses provide insight into where targeted interventions, such as protocolization and education, would be most beneficial. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Venous Thrombosis: Current Status and Future Directions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop